Trailing-twelve-month (TTM) revenue is $290.54 Million with a year-over-year growth of +54.89%. Revenue represents the total income generated from the company's primary business operations.
Trailing-12-month revenue adds these four fiscal quarters. Amounts are in USD, rounded only to whole currency units.
| Fiscal period | Revenue | Source |
|---|---|---|
| Q3 FY2025Period ended 2025-09-30 | $115,461,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2025-11-07 |
| Q4 FY2025Period ended 2025-12-31 | $59,666,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-02-27 |
| Q1 FY2026Period ended 2026-03-31 | $51,722,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-05-08 |
| Q2 FY2026Period ended 2026-06-30 | $63,693,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-08-07 |
| TTM revenue | $290,542,000 |
Current P/S: $5,948,788,137 market capitalization ÷ $290,542,000 TTM revenue = 20.47x.
Market capitalization source: FMP quote. Quote observed 2026-10-06T14:55:25.000Z. Latest revenue period ended 2026-06-30.
Current market capitalization comes from the quote provider. EPS weighted-average shares are a separate measure.
These references are supplied through FMP. Full filing context identifiers and dimensional metadata are unavailable in the normalized feed.
Reported quarterly revenue; no daily interpolation. Q2 FY2026 (2026-06-30): $63.69M.
FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters Quote observation: 2026-10-06T14:57:39.301Z. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation. Historical series through 2026-10-05.
Selected amounts supplied by FMP for each displayed period. Reviewed label references appear where available; other labels are unverified, and items may overlap.
2025-12-31 · USD
Reviewed labels link to their filing; other labels are unverified FMP source labels.
FMP selected disclosures by reporting period. Rows match exact source labels; they may overlap. N/A means no matching disclosure, not zero. Filing links identify reviewed presentation labels for that period.
| FMP source label (unverified unless linked) | FY20202020-12-31 · USD | FY20212021-12-31 · USD | FY20222022-12-31 · USD | FY20232023-12-31 · USD | FY20242024-12-31 · USD | FY20252025-12-31 · USD |
|---|---|---|---|---|---|---|
| Contract Revenue | $43M | $64M | $19M | $19M | $27M | $67M |
| Financial Royalty Assets | N/A | N/A | N/A |
$290.54M
$290.54 Million
+54.89%
vs. $187.58M a year ago (TTM)
+2.92%
5 Year compound annual growth rate
1 Year
+54.89%
3 Year
+22.87%
5 Year
+2.92%
10 Year
+12.68%
15 Year
+18.39%
20 Year
+2.12%
CAGR shows the annualized growth rate over the specified period, smoothing out year-to-year volatility.
| Year | Revenue | YoY Change | % Change |
|---|---|---|---|
| 2025 | $268.09M | +$100.95M | +60.40% |
| 2024 | $167.13M | +$35.82M | +27.28% |
| 2023 | $131.31M | ($64.93M) | (33.09%) |
| 2022 | $196.25M | ($45.30M) | (18.75%) |
| 2021 | $241.54M | +$77.98M | +47.68% |
| 2020 |
TTM Growth
+54.89%
3-Year CAGR
+22.87%
5-Year CAGR
+2.92%
Revenue growth vs the same fiscal quarter in the prior fiscal year, last 40 comparable quarters.
Current FMP quote-based enterprise value / four-quarter revenue Quote observation: 2026-10-06T14:57:39.301Z. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation. Historical series through 2026-10-05.
Reviewed presentation labels and parent/child details link to filing evidence; other FMP source labels remain unverified. Mutual exclusivity and reconciliation to a total for the same reporting period and currency have not been verified; percentages and stacked totals are unavailable.
| N/A |
| $13M |
| $28M |
| Intangible Royalty Assets | N/A | N/A | N/A | N/A | $95M | $133M |
|---|
| License Fees | $4M | $5M | $3M | $217,000 | $2M | $7M |
|---|
| License Fees, Milestones, and Other Product, Other | $5M | $6M | $6M | $1M | N/A | N/A |
|---|
| Material Sales, Captisol | $110M | $164M | $104M | $28M | $31M | N/A |
|---|
| Material Sales, Captisol, Core | N/A | N/A | $16M | $28M | $31M | $40M |
|---|
| Material Sales, Captisol, COVID | N/A | N/A | $88M | N/A | N/A | N/A |
|---|
| Milestone | $12M | $29M | $9M | $17M | N/A | N/A |
|---|
| Royalty | N/A | $49M | $73M | $84M | $109M | $161M |
|---|
| Royalty, Evomela | N/A | $10M | $10M | $10M | $9M | $6M |
|---|
| Royalty, Kyprolis | N/A | $27M | $30M | $36M | $38M | $36M |
|---|
| Royalty, Other | N/A | $11M | $8M | $13M | $9M | $10M |
|---|
| Service | $22M | $24M | $1M | $615,000 | $26M | $7M |
|---|
| $163.56M |
| +$43.28M |
| +35.98% |
| 2019 | $120.28M | ($131.17M) | (52.17%) |
| 2018 | $251.45M | +$110.35M | +78.21% |
| 2017 | $141.10M | +$32.13M | +29.48% |
| 2016 | $108.97M | +$37.06M | +51.53% |
